Neurocrine announces results of published study on tardive dyskinesia

Neurocrine announced that new data from RE-KINECT real-world, observational, multicenter study of antipsychotic-treated patients with possible tardive dyskinesia, was published in the Journal of Patient-Reported Outcomes. The analysis assessed the effects of possible TD, defined as clinician-confirmed presence of abnormal involuntary movements, on patient health and social functioning. It demonstrated that it’s important for clinicians to not only assess possible presence and severity of TD, but to also assess patient awareness of their own abnormal movements and the impact of these symptoms on the patients’ overall wellness and ability to function to determine optimal management strategies.